Visual abstract | Early guselkumab intervention in psoriasis leads to 'clinical super response': Week 28 results from the phase IIb GUIDE study

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing Week 28 data from the ongoing phase IIIb GUIDE study, investigating the efficacy of guselkumab in patients with moderate-severe plaque psoriasis with either a short disease duration (<2 years) and or a long disease duration (>2 years).¹

Key baseline patient characteristics are shown in Table 1. The baseline mean psoriasis area and severity and dermatology life quality index scores were similar between the groups.¹

Table 1. Baseline patient characteristics*

DLQI, Dermatology Life Quality Index; LDD, long disease duration; PASI, Psoriasis Area and Severity Index; SDD, short disease duration. *Adapted from Schäkel, et al.1
Characteristic, % unless otherwise stated	SDD (N = 357)	LDD (N = 523)	Overall (N = 880)
Sex
Female	31.9	27.9	29.5
Male	68.1	72.1	70.5
Age at baseline, years
<45	62.5	50.5	55.3
45–65	30.8	42.6	37.8
>65	6.7	6.9	6.8
Mean disease duration, years	1.2	20.2	12.5
Mean PASI, score	18.7	19.4	19.1
Mean DLQI, score	19.1	18.9	19.0
Patients with prior systemic and/or biologic therapy	24.6	68.3	50.6

The results from this study have demonstrated that early intervention with guselkumab in patients with psoriasis may lead to a better clinical response, which could lead to overall better long-term outcomes for patients.¹